Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
Although the association of ticlopidine and aspirin has been shown to be superior to anti-vitamin K agents and aspirin after coronary stent implantation in low-risk patients, the latter combination has remained an unproven reference regimen for high-risk patients until recently. We randomized 350 hi...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 98; no. 20; pp. 2126 - 2132 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
17.11.1998
American Heart Association, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Although the association of ticlopidine and aspirin has been shown to be superior to anti-vitamin K agents and aspirin after coronary stent implantation in low-risk patients, the latter combination has remained an unproven reference regimen for high-risk patients until recently.
We randomized 350 high-risk patients within 6 hours after stent implantation to receive during 30 days either aspirin 250 mg and ticlopidine 500 mg/d (A+T group) or aspirin 250 mg/d and oral anticoagulation (A+OAC group) targeted at an international normalized ratio of 2.5 to 3. The primary composite end point was defined as the occurrence of cardiovascular death, myocardial infarction, or repeated revascularization at 30 days. Patients were eligible if (1) the stent(s) were implanted to treat abrupt closure after PTCA; (2) the angiographic result after implantation was suboptimal; (3) a long segment was stented (>45 mm and/or >/=3 stents); or (4) the largest balloon inflated in the stent had a nominal diameter of </=2.5 mm. The primary cardiac end point was reached for 10 patients (5.6%) in the A+T group and 19 (11%) in the A+OAC group (relative risk [RR], 1. 9; 95% CI, 0.9 to 4.1; P=0.07). Major vascular and bleeding complications were less frequent in the A+T group (3 patients, 1.7%) than in the A+OAC group (12 patients, 6.9%) (RR, 4.1; 95% CI, 1.2 to 14.3; P=0.02).
High-risk patients should be treated with A+T rather than A+OAC after coronary stenting because the bleeding and vascular complications are significantly reduced and there is a marked trend suggesting a decrease in cardiac events. |
---|---|
AbstractList | Background
—Although the association of ticlopidine and aspirin has been shown to be superior to anti–vitamin K agents and aspirin after coronary stent implantation in low-risk patients, the latter combination has remained an unproven reference regimen for high-risk patients until recently.
Methods and Results
—We randomized 350 high-risk patients within 6 hours after stent implantation to receive during 30 days either aspirin 250 mg and ticlopidine 500 mg/d (A+T group) or aspirin 250 mg/d and oral anticoagulation (A+OAC group) targeted at an international normalized ratio of 2.5 to 3. The primary composite end point was defined as the occurrence of cardiovascular death, myocardial infarction, or repeated revascularization at 30 days. Patients were eligible if (1) the stent(s) were implanted to treat abrupt closure after PTCA; (2) the angiographic result after implantation was suboptimal; (3) a long segment was stented (>45 mm and/or ≥3 stents); or (4) the largest balloon inflated in the stent had a nominal diameter of ≤2.5 mm. The primary cardiac end point was reached for 10 patients (5.6%) in the A+T group and 19 (11%) in the A+OAC group (relative risk [RR], 1.9; 95% CI, 0.9 to 4.1;
P
=0.07). Major vascular and bleeding complications were less frequent in the A+T group (3 patients, 1.7%) than in the A+OAC group (12 patients, 6.9%) (RR, 4.1; 95% CI, 1.2 to 14.3;
P
=0.02).
Conclusions
—High-risk patients should be treated with A+T rather than A+OAC after coronary stenting because the bleeding and vascular complications are significantly reduced and there is a marked trend suggesting a decrease in cardiac events. BACKGROUND: Although the association of ticlopidine and aspirin has been shown to be superior to anti-vitamin K agents and aspirin after coronary stent implantation in low-risk patients, the latter combination has remained an unproven reference regimen for high-risk patients until recently. METHODS AND RESULTS: We randomized 350 high-risk patients within 6 hours after stent implantation to receive during 30 days either aspirin 250 mg and ticlopidine 500 mg/d (A+T group) or aspirin 250 mg/d and oral anticoagulation (A+OAC group) targeted at an international normalized ratio of 2.5 to 3. The primary composite end point was defined as the occurrence of cardiovascular death, myocardial infarction, or repeated revascularization at 30 days. Patients were eligible if (1) the stent(s) were implanted to treat abrupt closure after PTCA; (2) the angiographic result after implantation was suboptimal; (3) a long segment was stented (45 mm and/or /=3 stents); or (4) the largest balloon inflated in the stent had a nominal diameter of /=2.5 mm. The primary cardiac end point was reached for 10 patients (5.6%) in the A+T group and 19 (11%) in the A+OAC group (relative risk [RR], 1. 9; 95% CI, 0.9 to 4.1; P=0.07). Major vascular and bleeding complications were less frequent in the A+T group (3 patients, 1.7%) than in the A+OAC group (12 patients, 6.9%) (RR, 4.1; 95% CI, 1.2 to 14.3; P=0.02). CONCLUSIONS: High-risk patients should be treated with A+T rather than A+OAC after coronary stenting because the bleeding and vascular complications are significantly reduced and there is a marked trend suggesting a decrease in cardiac events. Although the association of ticlopidine and aspirin has been shown to be superior to anti-vitamin K agents and aspirin after coronary stent implantation in low-risk patients, the latter combination has remained an unproven reference regimen for high-risk patients until recently. We randomized 350 high-risk patients within 6 hours after stent implantation to receive during 30 days either aspirin 250 mg and ticlopidine 500 mg/d (A+T group) or aspirin 250 mg/d and oral anticoagulation (A+OAC group) targeted at an international normalized ratio of 2.5 to 3. The primary composite end point was defined as the occurrence of cardiovascular death, myocardial infarction, or repeated revascularization at 30 days. Patients were eligible if (1) the stent(s) were implanted to treat abrupt closure after PTCA; (2) the angiographic result after implantation was suboptimal; (3) a long segment was stented (>45 mm and/or >/=3 stents); or (4) the largest balloon inflated in the stent had a nominal diameter of </=2.5 mm. The primary cardiac end point was reached for 10 patients (5.6%) in the A+T group and 19 (11%) in the A+OAC group (relative risk [RR], 1. 9; 95% CI, 0.9 to 4.1; P=0.07). Major vascular and bleeding complications were less frequent in the A+T group (3 patients, 1.7%) than in the A+OAC group (12 patients, 6.9%) (RR, 4.1; 95% CI, 1.2 to 14.3; P=0.02). High-risk patients should be treated with A+T rather than A+OAC after coronary stenting because the bleeding and vascular complications are significantly reduced and there is a marked trend suggesting a decrease in cardiac events. |
Author | URBAN, P RUPPRECHT, H.-J EMANUELSSON, H KIEMENEIJ, F PIEPER, M FONTANELLI, A MACAYA, C WESSELING, T SAGNARD, L |
Author_xml | – sequence: 1 givenname: P surname: URBAN fullname: URBAN, P organization: Department of Cardiology: La Tour Hospital, Genève, Switzerland – sequence: 2 givenname: C surname: MACAYA fullname: MACAYA, C organization: Hospital Clinico San Carlos, Madrid, Spain – sequence: 3 givenname: H.-J surname: RUPPRECHT fullname: RUPPRECHT, H.-J organization: Klinikum der Jonannes-Gutenberg-Universität, Mainz, Germany – sequence: 4 givenname: F surname: KIEMENEIJ fullname: KIEMENEIJ, F organization: Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands – sequence: 5 givenname: H surname: EMANUELSSON fullname: EMANUELSSON, H organization: Sahlgrenska Hospital, Gothenburg, Sweden – sequence: 6 givenname: A surname: FONTANELLI fullname: FONTANELLI, A organization: Ospedale S. Maria delta Misericordia, Udine, Italy – sequence: 7 givenname: M surname: PIEPER fullname: PIEPER, M organization: Herzzentrum Bodensee, Kreuzlingen, Switzerland – sequence: 8 givenname: T surname: WESSELING fullname: WESSELING, T organization: Sanofi Recherche, Paris, France – sequence: 9 givenname: L surname: SAGNARD fullname: SAGNARD, L organization: Sanofi, Paris, France |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1580160$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9815866$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUctu1DAUtVCrMi18AAskC7EoiwQ7ThybXTUCOlIRUhnW0U3szLgkdmo7lcpf9o9wO1FRV9Y99zyufE7RkXVWI_SOkpxSTj8Tmq8317kUeUHyghb8FVrRqiizsmLyCK0IITKrWVG8Rqch3KSRs7o6QSdS0EpwvkIP12CVG81frbC-g2GGaJzFrsdgo-kc7ObhAN1pH-bwBE8J0oOOOO61h-keQx-1x53zzoK_xyFqG7EZE8_Gg9pYvDe7feZN-IOnhCVG-IK3e43HeUhJaU4WECbjEzcdhRM4uMkoYzWO3sCwxBgbPbzMMnaHz39cbLebX5_eoOMehqDfLu8Z-v3t63Z9mV39_L5ZX1xlHSt5zITUQgAoJljLy7oVkkJbVLqiraC8J0B4CyDLUnZVq1oGolO1KlWlu_RzTLEz9OHgO3l3O-sQmxs3e5sim8cmalYWZSLRA6nzLgSv-2byZkx3N5Q0jxU2hDapwkaKpiBPwqR5vxjP7ajVs2LpLO0_LnsIHQy9B9uZ8N-4EoRywv4BfXOslA |
CODEN | CIRCAZ |
Cites_doi | 10.1136/hrt.66.5.337 10.1016/S0002-8703(07)80006-8 10.1002/(SICI)1097-0304(199703)40:3<265::AID-CCD9>3.0.CO;2-8 10.1056/NEJM199408253310811 10.1161/01.CIR.93.3.412 10.1002/ccd.1810320208 10.1016/S0735-1097(96)00431-7 10.1161/circ.85.3.1537128 10.1161/circ.78.5.3180371 10.1056/NEJM199604253341702 10.1016/S0140-6736(96)09457-3 10.1016/S0735-1097(97)00395-1 10.1161/circ.86.3.1516193 10.1161/01.CIR.91.6.1676 10.1097/00019501-199504000-00012 10.1177/106002809402801103 10.1056/NEJM199101033240103 10.1016/0735-1097(93)90093-G 10.1161/circ.95.8.2015 10.1056/NEJM198908243210804 10.1161/circ.94.7.1519 10.1093/oxfordjournals.eurheartj.a015072 10.1056/NEJM198703193161201 10.1016/S0002-8703(07)80005-6 10.1016/0002-9149(90)90522-3 10.1161/circ.95.5.1098 10.1161/circ.93.2.215 10.1056/NEJM199408253310801 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS Copyright American Heart Association, Inc. Nov 17, 1998 |
Copyright_xml | – notice: 1999 INIST-CNRS – notice: Copyright American Heart Association, Inc. Nov 17, 1998 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. NAPCQ U9A |
DOI | 10.1161/01.CIR.98.20.2126 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Career and Technical Education (Alumni Edition) |
DatabaseTitleList | CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 2132 |
ExternalDocumentID | 36072744 10_1161_01_CIR_98_20_2126 9815866 1580160 |
Genre | Multicenter Study Comparative Study Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 0ZK 18M 1CY 1J1 29B 2FS 2WC 354 40H 41~ 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ 8W4 AAAXR AAEJM AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AARTV AASOK AASXQ AAWTL AAXQO AAYOK ABASU ABBUW ABDIG ABFLS ABOCM ABPMR ABPTK ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACOAL ACRKK ACRZS ACWDW ACWRI ACXNZ ADBBV ADCYY ADFPA ADGIM ADNKB AE3 AE6 AEBDS AENEX AFCHL AFDTB AFFNX AFUWQ AGINI AHMBA AHRYX AHVBC AIJEX AJIOK AJJEV AJNYG AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR ASPBG AVWKF AWKKM AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EJD EX3 F2K F2L F2M F2N F5P FEDTE FL- FW0 GQDEL GX1 H0~ H13 HVGLF HZ~ H~9 IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 MVM N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OJAPA OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQEST PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YQJ YSK YXB YYM YYP YZZ ZA5 ZFV ZGI ZXP ZY1 ZZMQN ~H1 AAAAV AAIQE AAUEB ABJNI ACILI ADGGA ADHPY AEETU AFEXH AHOMT AHQNM AINUH AJNWD AJZMW AMNEI CGR CUY CVF ECM EIF FCALG NPM AAYXX CITATION K9. NAPCQ U9A |
ID | FETCH-LOGICAL-c346t-89e88aad383b647b891ab25e51b816f0a06baa9449c5bdb3a8cd7d4d5ec5863d3 |
ISSN | 0009-7322 |
IngestDate | Thu Oct 10 19:13:25 EDT 2024 Fri Aug 23 01:07:22 EDT 2024 Sat Sep 28 08:39:05 EDT 2024 Thu Nov 24 18:30:42 EST 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 20 |
Keywords | Human Endoprosthesis Drug combination Prognosis Coronary artery Instrumentation therapy Anticoagulant Instrumental dilatation Acetylsalicylic acid Survival Antiplatelet agent Ticlopidine Chemotherapy Treatment Follow up study Salicylates Comparative study |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c346t-89e88aad383b647b891ab25e51b816f0a06baa9449c5bdb3a8cd7d4d5ec5863d3 |
PMID | 9815866 |
PQID | 212673424 |
PQPubID | 24119 |
PageCount | 7 |
ParticipantIDs | proquest_journals_212673424 crossref_primary_10_1161_01_CIR_98_20_2126 pubmed_primary_9815866 pascalfrancis_primary_1580160 |
PublicationCentury | 1900 |
PublicationDate | 1998-11-17 |
PublicationDateYYYYMMDD | 1998-11-17 |
PublicationDate_xml | – month: 11 year: 1998 text: 1998-11-17 day: 17 |
PublicationDecade | 1990 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States – name: Baltimore |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 1998 |
Publisher | Lippincott Williams & Wilkins American Heart Association, Inc |
Publisher_xml | – name: Lippincott Williams & Wilkins – name: American Heart Association, Inc |
References | e_1_3_2_26_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_1_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 (e_1_3_2_24_2) 1996; 28 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 (e_1_3_2_25_2) 1996; 8 (e_1_3_2_27_2) 1996; 28 |
References_xml | – ident: e_1_3_2_8_2 doi: 10.1136/hrt.66.5.337 – volume: 28 start-page: 782 year: 1996 ident: e_1_3_2_24_2 publication-title: J Am Coll Cardiol – ident: e_1_3_2_11_2 doi: 10.1016/S0002-8703(07)80006-8 – ident: e_1_3_2_29_2 doi: 10.1002/(SICI)1097-0304(199703)40:3<265::AID-CCD9>3.0.CO;2-8 – ident: e_1_3_2_5_2 doi: 10.1056/NEJM199408253310811 – ident: e_1_3_2_23_2 – ident: e_1_3_2_20_2 – ident: e_1_3_2_18_2 doi: 10.1161/01.CIR.93.3.412 – ident: e_1_3_2_13_2 doi: 10.1002/ccd.1810320208 – ident: e_1_3_2_28_2 doi: 10.1016/S0735-1097(96)00431-7 – ident: e_1_3_2_3_2 doi: 10.1161/circ.85.3.1537128 – ident: e_1_3_2_2_2 doi: 10.1161/circ.78.5.3180371 – ident: e_1_3_2_22_2 doi: 10.1056/NEJM199604253341702 – ident: e_1_3_2_26_2 – ident: e_1_3_2_33_2 doi: 10.1016/S0140-6736(96)09457-3 – ident: e_1_3_2_34_2 doi: 10.1016/S0735-1097(97)00395-1 – ident: e_1_3_2_9_2 doi: 10.1161/circ.86.3.1516193 – ident: e_1_3_2_17_2 doi: 10.1161/01.CIR.91.6.1676 – ident: e_1_3_2_16_2 doi: 10.1097/00019501-199504000-00012 – ident: e_1_3_2_32_2 doi: 10.1177/106002809402801103 – ident: e_1_3_2_6_2 doi: 10.1056/NEJM199101033240103 – ident: e_1_3_2_10_2 doi: 10.1016/0735-1097(93)90093-G – ident: e_1_3_2_30_2 doi: 10.1161/circ.95.8.2015 – volume: 8 start-page: 185 year: 1996 ident: e_1_3_2_25_2 publication-title: J Invas Cardiol – ident: e_1_3_2_31_2 doi: 10.1056/NEJM198908243210804 – ident: e_1_3_2_14_2 doi: 10.1161/circ.94.7.1519 – ident: e_1_3_2_15_2 doi: 10.1093/oxfordjournals.eurheartj.a015072 – ident: e_1_3_2_1_2 doi: 10.1056/NEJM198703193161201 – ident: e_1_3_2_12_2 doi: 10.1016/S0002-8703(07)80005-6 – ident: e_1_3_2_7_2 doi: 10.1016/0002-9149(90)90522-3 – ident: e_1_3_2_19_2 doi: 10.1161/circ.95.5.1098 – ident: e_1_3_2_21_2 doi: 10.1161/circ.93.2.215 – ident: e_1_3_2_4_2 doi: 10.1056/NEJM199408253310801 – volume: 28 start-page: 827 year: 1996 ident: e_1_3_2_27_2 publication-title: Cardiol |
SSID | ssj0006375 |
Score | 2.210329 |
Snippet | Although the association of ticlopidine and aspirin has been shown to be superior to anti-vitamin K agents and aspirin after coronary stent implantation in... Background —Although the association of ticlopidine and aspirin has been shown to be superior to anti–vitamin K agents and aspirin after coronary stent... BACKGROUND: Although the association of ticlopidine and aspirin has been shown to be superior to anti-vitamin K agents and aspirin after coronary stent... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 2126 |
SubjectTerms | Adult Aged Anticoagulants - therapeutic use Aspirin - adverse effects Aspirin - therapeutic use Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Coronary Thrombosis - prevention & control Female Humans Male Medical sciences Middle Aged Patient Compliance Pharmacology. Drug treatments Platelet Aggregation Inhibitors - therapeutic use Stents - adverse effects Ticlopidine - adverse effects Ticlopidine - therapeutic use |
Title | Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9815866 https://www.proquest.com/docview/212673424 |
Volume | 98 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEGgSQrAxUcaQHxACppTmy7F5qyZGByoPpZX2FtlOgiLRJOrHw_Zf8sw_w_kjTdJtEvASVU5sJ71fLufz7-4Qei05I9xlqRPxbOgELAA9CGaRQ0REUl-qWEwVnDz5Rsbz4MtleNnr_W6xljZrMZDXt8aV_I9UoQ3kqqJk_0Gy20GhAX6DfOEIEobjX8l4youkXOTXYDQ2Wbv1zn4B15b8h63Ndaq4F5uVbq6gCT41OoRR5ROwVcKlymSgGHQg9WKtgid_8sIyEfPiVGU1djQN3SZiXdWEEM1IVBRPGISrbfvc0JvVzZZVnigr1pQGMRPlypvcnc16Kyaj2ezie-2aqLMn5EtZP8UthYNajoz5Uhhn7jZibcIlv-IdV_B0U1Wg440_YtzsiX3NlZs0NXtZ540rRMcGKjpe1FHvzIl8r6PeGW3B2Bt2lLUJ1r_5FSGujowYnF1MB0wRAAe718KfXC00rBh1Q0p20nlrA8GeuYfuexELFd_082XDPyJ-FNZl_tQ92y13mPvDjZn30QM7WMd8elTxFbzJmSnBcvcaSdtKsyfosV3k4JFB7FPUS4sDdDgq-LpcXOE3WNOO9X7OAXo4seyOQ_SrwTNu8IzLDO_gGRs84zaescUz1jDDNcKwRhhu4xnnBd7iGdd4_qgGwC00Y4tmmCXBLTRjjWY7TQfNuEYzfmuw_O4Zmp9_mp2NHVtyxJF-QNYOZSmlnCc-9QUJIkGZy4UXpqErqEuyIR8SwTkLAiZDkQifU5lESZCEqQTp-Il_hPaKskifI-wTsLU5BUXIRCDTTMgsCJnMSAbGCZdhH72vJRlXJrNMrFfkxI2HbgwAiBmNvWGsANBHJx1ZNz1CqnJE9tFxLfvYKqiV7hj5gRf00ZGBw7abRdOLu04co_3mBXuJ9tbLTXoC1vdavNIo_gOeQuI6 |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+evaluation+of+anticoagulation+versus+antiplatelet+therapy+after+coronary+stent+implantation+in+high-risk+patients%3A+the+multicenter+aspirin+and+ticlopidine+trial+after+intracoronary+stenting+%28MATTIS%29&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Urban%2C+P&rft.au=Macaya%2C+C&rft.au=Rupprecht%2C+H+J&rft.au=Kiemeneij%2C+F&rft.date=1998-11-17&rft.issn=0009-7322&rft.volume=98&rft.issue=20&rft.spage=2126&rft_id=info:doi/10.1161%2F01.CIR.98.20.2126&rft_id=info%3Apmid%2F9815866&rft.externalDocID=9815866 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |